ClinicalTrials.gg
Not yet recruitingNCT05159453LEVPSUpdated May 26, 2026

Dose Response Study of Transdermal Human Insulin in Patients

A Phase 2/3 interventional study of Human Insulin and Finger-actuated, Metered Pump Sprayer in Glucose, High Blood, sponsored by Transdermal Delivery Solutions Corp. Not yet recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Transdermal Delivery Solutions Corp · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
25 Years to 75 Years
Sex
All
01

Study summary

A 21-Day open label study of transdermally delivered human insulin in Type 2 Diabetics as measured by response of down modulation of glucose after dosing of Insulin as compared to historic patient response to injected insulins.

Read the detailed description

A 21-Day open label study of transdermally delivered human insulin in 30 Type 2 Diabetics is anticipated. Well-managed Type 2 Diabetics will be added to the protocol from the patient census of practicing diabetologists and family practitioners, with preference given to patients already using a wearable Continuous Glucose Monitor (CGM) system. Once added to the protocol, Subjects will be monitored via CGM for two weeks before change of dose form. Subjects will be required to calibrate the CGM against finger-stick blood sampling and to poll the monitor sensor at least every 8 hours during the 42 days of monitoring including the 21-days on-transdermal-dose study period to ensure continuity of interstitial glucose measurement. Subjects will be monitored for 7 days after the last transdermal dose to monitor interchangeability of the dose forms.

Once baseline data is collected, Subjects will exchange transdermal dosing on a Unit for Unit basis. Trial materials will be formulated to a concentration of 100 IUs per mL and dispensed via 0.2 mL metered, finger-actuated pump sprayer, with each pump delivering 20 IUs of Human Insulin to the skin. If a patient, for example is currently using 120 IUs per day, 40 IUs basal insulin and 80 IUs Insulin Aspart, 120 IUs or 6 sprays would be used.

The study nurse will contact each subject every day of the study to answer questions and encourage compliance with the protocol.

02

Conditions studied

  • Glucose, High Blood
03

In context

Lead sponsor

Transdermal Delivery Solutions Corp is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult Type 2 Diabetes Mellitus ("T2D") Patients on Insulin Replacement therapy not administered via implanted pump well-managing p.r.n as defined by serum glucose ranging between 85 and 200 mg/dL and no more than 1 hypoglycemic or serious hypoglycemic event within the last 9 months.
  2. 25 and 75 years of age, inclusive.
  3. The subject is willing and able to read and understand the Subject Information Sheet and provide written .
  4. The subject has a (BMI) within 18-50 kg/m2.
  5. The subject is in otherwise good health as determined by medical history and physical examination.
  6. The subject's normal insulin dose ranges from between 10 to 200 IU per dose.
  7. The subject must agree to continue with daily serum glucose testing by means of a wearable blood glucose monitor for the pharmacodynamic assessments that the investigators have continuous access to via daily downloads.
  8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
  9. The subject is willing and able to return to the study site for all visits.

Exclusion criteria

Exclusion Criteria:

  1. The subject has any relevant deviations from normal other than blood glucose in physical examination, (ECG), or clinical laboratory tests, as evaluated by the investigator.
  2. The subject has had more than 2 hypoglycemic events in the last month.
  3. The subject's normal insulin dose is less than 10 and more than 200 IUs.
  4. Subjects receiving Insulin from an implanted or external insulin pump system.
  5. The subject has had a illness or surgical procedure within 30 days preceding entry into this study.
  6. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease other than T2D.
  7. The subject has a known allergy or history of to Human Insulin or similar modified Insulin compounds.
  8. The subject has used any prescription medication that may interfere with the evaluation of study medication.
  9. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and subject's concentration and hematocrit have not returned to within 5% of normal.
  10. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
  11. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
  12. Subjects who have received an drug or have used an investigational device in the 30 days prior to study entry.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Main Experimental

    Type 2 Diabetic patients regulating blood glucose with daily injections as basal and/or post-prandial interventions. Patients will receive transdermal product formulated at 100 IU/mL of equivalent International Units of Human Insulin dosed at the same amount as current injected therapies with timing adjusted for the Absorption, Distribution, Metabolism \& Elimination (ADME) of human insulin with maximum effect at 3 hours post dose so mid morning before lunch, late afternoon before dinner and before bedtime.

    Biological: Human Insulin · Device: Finger-actuated, Metered Pump Sprayer

Interventions

  • BiologicalHuman Insulin

    International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.

    Also known as: Humulin(R), Novolin(R)

  • DeviceFinger-actuated, Metered Pump Sprayer

    Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.

06

What researchers measure

Primary outcomes

  1. Percentage of Glucose Time in Range for Study Participants

    Number of Participants who manage blood glucose in study participants to between 70 and 200 mg Glucose / dL.

    Time frame: 21 Days

Secondary outcomes

  1. Avoidance of Hypoglycemia in Study Participants

    Number of study participants that manage blood glucose in study participants to more than 50 mg/dL for 86% of the 21-days-on-dose of the study period

    Time frame: 21 days.

  2. Skin Safety in Study Participants

    Measure of skin irritation above level 1 - erythema \& edema - according to the The Organisation for Economic Co-operation and Development (OECD) Guideline for Testing of Chemicals No. 404, adopted 17th July, 1992: "Acute Dermal Irritation/Corrosion"

    Time frame: 21 days dosing plus 7 days post dose follow-up.

07

Study locations

1 site
  • Langford Research Institute
    Palm Beach Gardens, Florida 33410, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2027; primary completion for Oct 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 16, 2021
StartEst.
Sep 2, 2027
Primary completionEst.
Oct 15, 2027
CompletionEst.
Dec 15, 2027
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05159453
Lead sponsor
Transdermal Delivery Solutions Corp
Collaborators
Langford Research Institute, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Sep 2, 2027 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
May 26, 2026

Study contacts

Kenneth B. Kirby, BA
Contact
KKirby@Langfordresearch.org
5614296429
Gordon von Nehring, PhD
Contact
gordon@langfordresearch.com
551-580-5978
Chandan A.S. Alam, MD
principal investigator · Langford Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion